KLDO - Kaleido extends timeline for data readout on KB109 in COVID-19

Citing updated enrollment projections, Kaleido Biosciences (KLDO) now expects to report topline data from its K031 study evaluating KB109 in patients with mild-to-moderate COVID-19 in Q1 2021 instead of this quarter.Results from another study, KB032, testing KB109 in the same patient population should be available next quarter as well.Guidance on other programs remains as is.KB109 is a Microbiome Metabolic Therapy ((MMT)), specifically a synthetic glycan, a chain-like structure of sugar molecules that plays an essential role in every biological process in the body.

For further details see:

Kaleido extends timeline for data readout on KB109 in COVID-19